3 completed, 1 active not recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Completed 2 |
Follow PT2385: new trials by email Literature Review of PT2385 trials Research Report on PT2385
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma HIF-2alpha Inhibitor PT2385, Pharmacological Study, Laboratory Biomarker Analysis - Recurrent Glioblastoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 24 | 2017-09-14 | 2022-05-09 |
| MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) MK-3795 - VHL Gene Mutation, VHL | Phase 2 | Completed | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 4 | 2017-04-24 | 2024-09-24 |
| PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers PT2385 - Healthy | Phase 1 | Completed | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 16 | 2015-09-01 | 2015-12-10 |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) MK-3795, Nivolumab, Cabozantinib - ccRCC, RCC | Phase 1 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 110 | 2014-11-25 | 2024-06-17 |
Carcinoma, Renal Cell (2) · Glioblastoma (1) · Kidney Neoplasms (1) · von Hippel-Lindau Disease (1)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (4)
Roy Strowd, MD (1)
PMID 29257710, PMID 34783716, PMID 37864646
UM1CA137443 (1)